Amarin Corp Plcuk (AMRN) Total Liabilities (2010 - 2026)
Amarin Corp Plc\Uk (AMRN) posted quarterly Total Liabilities of $180.7 million for Q2 2026, down 11.92% year-over-year from $205.2 million in Q2 2025, and down 7.95% quarter-over-quarter from $196.4 million in Q1 2026.
Amarin Corp Plcuk (AMRN) Total Liabilities (2010 - 2026) Analysis & Trends
Amarin Corp Plc\Uk (AMRN) has reported Total Liabilities for 17 consecutive years, with $180.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Liabilities fell 11.92% year-over-year to $180.7 million; the TTM figure through Jun 2026 stood at $180.7 million (down 11.92% YoY), while the FY2025 annual figure was $211.5 million, up 6.19% from the prior year.
- Total Liabilities fell to $180.7 million in Q2 2026 per AMRN's latest filing, from $196.4 million in the prior quarter.
- Across five years, Total Liabilities topped out at $393.2 million in Q2 2022 and bottomed at $180.7 million in Q2 2026.
- Historically, Total Liabilities has averaged $253.1 million across 5 years, with a median of $246.0 million in 2024.
- Annual changes were most pronounced in 2024 — Total Liabilities declined 28.76% — and 2026, when it grew 7.89%.
- Amarin Corp Plc\Uk's Total Liabilities stood at $290.8 million in 2022, then slipped by 3.87% to $279.6 million in 2023, then slipped by 28.76% to $199.2 million in 2024, then increased by 6.19% to $211.5 million in 2025, then dropped by 14.54% to $180.7 million in 2026.
- Business Quant data shows AMRN's Total Liabilities at $180.7 million in Q2 2026, $196.4 million in Q1 2026, and $211.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.30 Bn | 630.54 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 468.64 Bn | 462.07 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 378.89 Bn | 371.74 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 300.89 Bn | 293.20 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Astrazeneca | 257.36 Bn | 252.46 Bn | 12.86 Bn | 65.46 Bn |
| 6 | Amgen | 236.69 Bn | 222.70 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 182.15 Bn | 178.97 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 161.31 Bn | 149.61 Bn | 10.94 Bn | 115.64 Bn |
| 9 | Gsk | 105.67 Bn | 101.50 Bn | 8.24 Bn | -59.79 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.53 Bn | 14.99 Mn | 180.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 180.75 Mn |
| Mar 31, 2026 | 196.35 Mn |
| Dec 31, 2025 | 211.49 Mn |
| Sep 30, 2025 | 200.92 Mn |
| Jun 30, 2025 | 205.20 Mn |
| Mar 31, 2025 | 181.99 Mn |
| Dec 31, 2024 | 199.17 Mn |
| Sep 30, 2024 | 219.24 Mn |
| Jun 30, 2024 | 247.98 Mn |
| Mar 31, 2024 | 244.08 Mn |
| Dec 31, 2023 | 279.59 Mn |
| Sep 30, 2023 | 285.88 Mn |
| Jun 30, 2023 | 290.89 Mn |
| Mar 31, 2023 | 275.40 Mn |
| Dec 31, 2022 | 290.85 Mn |
| Sep 30, 2022 | 320.48 Mn |
| Jun 30, 2022 | 393.19 Mn |
| Mar 31, 2022 | 332.60 Mn |
| Dec 31, 2021 | 400.97 Mn |
| Sep 30, 2021 | 393.31 Mn |